This is a working overview of NR1D2, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-10. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Viv Groskop (born 8 July 1973) of Polish Jewish ancestry, journalist, writer and comedian; has written for publications including The Guardian, Evening Standard, The Observer, Daily Mail, Mail on Sunday and Red magazine. She writes on arts, books, popular culture and current affairs, identifying as a feminist. Groskop is a stand-up comedian, MC and improviser who was a finalist in Funny Women 2012 and semi-finalist in So You Think You're Funny 2012.
=== Alloantibody formation and clinical significance === When talking about the ABO blood group system, Landsteiner's Law states that if an individual possesses the A and/or B antigen, they will not form antibodies to these antigens. However, if an individual does not have either A or B antigens, they will naturally produce anti-A and anti-B antibodies. According to the International Society of Blood Transfusion (ISBT), 47 blood group systems containing hundreds of different red blood cell antigens have been described. With some exceptions, many non-ABO blood group system antigens require a sensitizing event to stimulate antibody production. In other words, the immune system must be exposed to the antigen in order to elicit antibody production. Exposure to antigens can occur through blood transfusion, stem cell/bone marrow transplant, and pregnancy. The clinical significance of an alloantibody depends on its ability to cause a decrease in donor red blood cell survival. Characteristics of clinically significant alloantibodies include: immunoglobulin G antibody subclass, reactivity at body temperature, and ability to cause red blood cell agglutination in the presence of anti-human globulin (AHG) in an indirect antiglobulin test. Sometimes, clinical significance of an antibody can be difficult to determine. Antibodies to high prevalence red cell antigens can sometimes mask the detection of clinically significant alloantibodies because the corresponding antigen is present on most, if not all, of the screening red blood cells used to detect these antibodies possess the antigen.
Pantopon, also known as Opium Alkaloids Hydrochlorides, is a preparation of opiates made up of all of the alkaloids present in opium in their natural proportions as hydrochlorides salts. It can sometimes be tolerated by people who are allergic to morphine. Pantopon is prepared by treating standardized medicinal opium with hydrochloric acid or, more commonly, mixing 20 parts morphine HCl, 5 parts codeine, 6 parts thebaine, 8 parts noscapine, 2 parts narcotine, 6 parts miscellaneous alkaloids hydrochlorides. Pantopon is, in other words, opium with all of the tar and other insolubles removed in an injectable form which, by weight, is nearly as potent as morphine. It was invented in 1909 by the Hoffmann-La Roche pharmaceutical company. Other drugs of the same type have included in the opium alkaloid hydrobromides, sulfates, phosphates, and valerates. "Opium in a syringe " and "Injectable Whole Opium" were common advertising slogans for the product from Roche. An example of similar product to Pantopon is Omnopon, which contains morphine, codeine, and papaverine.
Sources: en.wikipedia.org
The Bio-medical Waste (Management and Handling) Rules, 1998 and further amendments were passed for the regulation of bio-medical waste management. On 28 March 2016 Biomedical Waste Management Rules (BMW 2016) were also notified by Central Govt. Each state's Pollution Control Board or Pollution control Committee will be responsible for implementing the new legislation. New regulations affect the distribution of medical waste by medical professionals into their proper receptacles. Due to the competition to improve quality and so as to get accreditation from agencies like ISO, the NABH, JCI, and many private organizations have initiated proper biomedical waste disposal but still the gap is huge. Many studies took place in Gujarat, India regarding the knowledge of workers in facilities such as hospitals, nursing homes, or home health. It was found that 26% of doctors and 43% of paramedical staff were unaware of the risks related to biomedical wastes. After extensively looking at the different facilities, many were undeveloped in the area regarding biomedical waste. The rules and regulations in India work with The Bio-medical Waste (Management and Handling) Rules from 1998, yet a large number of health care facilities were found to be sorting the waste incorrectly. The National Green Tribunal (NGT) has been stringent on the application of the BMW 2016 over the past 12 months. There are now over 200 licensed Common Bio Medical Waste Treatment and Disposal Facilities (CBWTDF) or Common Treatment Facility (CTF) in the country.
The names of organic compounds are either systematic, following logically from a set of rules, or nonsystematic, following various traditions. Systematic nomenclature is stipulated by specifications from IUPAC (International Union of Pure and Applied Chemistry). Systematic nomenclature starts with the name for a parent structure within the molecule of interest. This parent name is then modified by prefixes, suffixes, and numbers to unambiguously convey the structure. Given that millions of organic compounds are known, rigorous use of systematic names can be cumbersome. Thus, IUPAC recommendations are more closely followed for simple compounds, but not complex molecules. To use the systematic naming, one must know the structures and names of the parent structures. Parent structures include unsubstituted hydrocarbons, heterocycles, and monofunctionalized derivatives thereof. Nonsystematic nomenclature is simpler and unambiguous, at least to organic chemists. Nonsystematic names do not indicate the structure of the compound. They are common for complex molecules, which include most natural products. Thus, the informally named lysergic acid diethylamide is systematically named (6aR,9R)-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg] quinoline-9-carboxamide. With the increased use of computing, other naming methods have evolved that are intended to be interpreted by machines. Two popular formats are SMILES and InChI.
You can't ask for much more from one of the definitive records of the 2000s." "No question about it," writes George Lang for NewsOK, "2002's “Mclusky Do Dallas” was the most hilarious record the Pixies never made, an album built from lacerating music and equally serrated wit that was custom-built for furious road trips and decibel therapy." Phoenix New Times ranked it third on their list of "10 Underrated Punk Albums That Should Be Considered Classics", with Tom Reardon writing: "Like the first two records on this list [Frankenchrist and Worlds Apart], this is a great record from a great band, but it has been largely ignored by way too many people. Sure, it's noisy and disrespectful to just about anyone with a shred of pop sensibility, but it also totally rocks."
Sources: en.wikipedia.org
== Development == The game was originally created and released by Daniel Fearon. At the time, Fearon was one of the maintainers of the Half-Life fan website Atomic Half-Life, created in anticipation of the game's release. Fearon was sent a copy of Half-Life by Valve prior to its official release, and while playing it, he toyed with the game's code, figuring out how to spawn enemy creatures in multiplayer maps. Fearon's work had initially been done before Valve released the software development kit for Half-Life, requiring him to craft the modification atop the existing Half-Life distribution and to work with multiplayer over slower internet connections, such as phone-line modems. Fearon initially developed a single map that could be played cooperatively, and later a second version with two maps. The first public version of Sven Co-op was released on January 19, 1999, about 3 months after the release of Half-Life. He used the name Sven Co-op to reflect his online handle, "Sven Viking". Contrary to the common belief that Sven Co-op was developed to play through Half-Life cooperatively, Fearon had wanted to create a means for players to engage in cooperative experiences together, often just spawning in large number of enemies for them to dispatch together on a single map. This drew a number of amateur level developers to craft mission-based maps for the mod, where players would be required to go to different areas on the map based on success or failure of a given objective.
Rattlesnakes are native to the Americas from southern Canada to central Argentina, with the majority of species inhabiting arid regions. The large majority of species live in the American Southwest and Mexico. Four species may be found east of the Mississippi River, and two in South America. In the United States, the state with the most types of rattlesnakes is Arizona, with 13. Rattlesnakes are found in almost every habitat type capable of supporting terrestrial ectothermic vertebrates, but individual species may have extremely specific habitat requirements, living where certain plant associations occur or within a narrow range of elevations. Most species live near open, rocky areas. Rocks offer them cover from predators, plentiful prey (e.g. rodents, lizards, insects, etc. that live amidst the rocks), and open basking areas. However, rattlesnakes can also be found in a wide variety of other habitats, including prairies, marshes, deserts, and forests. Rattlesnakes prefer a temperature range between 80 and 90 °F (27 and 32 °C), but can survive temperatures below freezing, recovering from brief exposure to temperatures as low as 4 °F (−16 °C), and surviving for several days in temperatures as low as 37 °F (3 °C). The most probable ancestral area of rattlesnakes is the Sierra Madre Occidental region in Mexico. The most probable vegetation or habitat of the ancestral area appears to be pine-oak forests.
=== Social policies: "Three Transformations" === Perhaps inspired by the Three Principles of the People, Liu Wenhui adopted a frontier policy known as the "Three Transformations" (san hua zhengce, 三化政策). Although described by Liu as a policy, it was closer to a loose model of governance. These three transformations included transformation through virtuous rule (de hua; 德化), transformation through assimilation (tong hua; 同化), and transformation through progress (jin hua; 進化). For Liu, virtuous rule was to win the hearts and minds of the non-Han populace, and progress would establish an interventionist, "fluid" government that avoided "static" stagnation under laissez-faire rule. However, Liu refrained from elucidating on the exact nature such progress would take. Liu also reportedly adopted different management styles for areas of Xikang depending on the ethnic group that inhabited them. For Tibetan areas, he advocated "steady progress" (稳进); for Han areas, "gradual progress" (逐进). Finally, for Yi areas, he called for "rapid progress" (猛进). These were called the "Three Advances" (三进主义). On the matter of ethnic policy, Liu's government was highly selective. Although his administration was relatively tolerant of Tibetans, even patronizing Tibetan Buddhism and establishing schools for Tibetan students, it was highly discriminatory against the Yi people, calling for the complete erasure of Yi identity. For many Han settlers in Xikang, the Yi were a "scourge", associated with violence and slave-raiding; the Yi, in turn, spoke of a "Han scourge".
Genetic research has produced several genetically modified varieties. 'New Leaf', owned by Monsanto Company, incorporates genes from Bacillus thuringiensis (source of most Bt toxins in transcrop use), which confers resistance to the Colorado potato beetle; 'New Leaf Plus' and 'New Leaf Y', approved by US regulatory agencies during the 1990s, also include resistance to viruses. McDonald's, Burger King, Frito-Lay, and Procter & Gamble announced they would not use genetically modified potatoes, and Monsanto published its intent to discontinue the line in March 2001. Potato starch contains two types of glucan, amylose and amylopectin, the latter of which is most industrially useful. Waxy potato varieties produce waxy potato starch, which is almost entirely amylopectin, with little or no amylose. BASF developed the 'Amflora' potato, which was modified to express antisense RNA to inactivate the gene for granule bound starch synthase, an enzyme which catalyzes the formation of amylose. 'Amflora' potatoes therefore produce starch consisting almost entirely of amylopectin, and are thus more useful for the starch industry. In 2010, the European Commission cleared the way for 'Amflora' to be grown in the European Union for industrial purposes only—not for food. Nevertheless, under EU rules, individual countries have the right to decide whether they will allow this potato to be grown on their territory. Commercial planting of 'Amflora' was expected in the Czech Republic and Germany in the spring of 2010, but due to lack of acceptance BASF in 2012 stopped selling the variety in Europe.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.